Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Inclusion Criteria: * Age 50-78 years old (Canada) * Age 60-78 years old (United States) * Diagnosis of Parkinson's Disease made between 3 to 20 years ago * Taking levodopa, but with complications of therapy such as wearing off and/or dyskinesia * Able to participate in all study visits and evaluations, including brain MRI and PET scan * Existence of a study partner who may act as potential surrogate over long term for ongoing consent Exclusion Criteria: * Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or other neurodegenerative diseases such as Alzheimer's disease * Prior Deep Brain Stimulation , lesion therapy, or gene therapy for PD * Prior surgical or radiation therapy to the brain or spinal cord * Any medical condition resulting in high risk of immunosuppressive drugs, including any active infectious disease * Inability to temporarily stop anti-platelet agents or other anti-coagulant medications without serious risk * Previous or currently active malignant disease within the past 5 years, except basal cell carcinoma or in situ uterine cervical carcinoma that have been treated * Severe obesity (\>350 lbs) or any condition that prevents use of PET/MRI * Pregnancy or breastfeeding * Contraindication to surgery or general anesthesia * In the opinion of the investigator, any other condition regarded as making subject unsuitable for trial